Mruthyunjaya Prithvi, Wirostko William J, Chandrashekhar Ravindra, Stinnett Sandra, Lai James C, Deramo Vincent, Tang Johnny, Dev Sundeep, Postel Eric A, Connor Thomas B, Fekrat Sharon
Duke University Eye Center, Durham, North Carolina 27710, USA.
Retina. 2006 Mar;26(3):285-91. doi: 10.1097/00006982-200603000-00006.
To describe the clinical features of persons who developed central retinal vein occlusion (CVO) while being treated with Coumadin for chronic anticoagulation.
In a retrospective, comparative, noninterventional case series of patients diagnosed with CVO while being treated with Coumadin as a systemic anticoagulant, visual and anatomical outcomes were compared with those for a cohort of patients diagnosed with CVO who were not treated with any systemic anticoagulation.
Fourteen eyes of 14 patients treated with Coumadin were identified. At presentation, the median international normalization ratio (INR) was 2.20 (range, 1.3-5.0). Eight patients (57%) had a therapeutic INR at the time of CVO. Their visual acuity and perfusion status were similar to those of patients with subtherapeutic INR. At the last follow-up (median, 16 months), visual acuity and perfusion status of the group of 14 eyes were similar to baseline findings (P = 0.62). Clinical features and outcomes were similar to those for a cohort of patients with CVO who were not being treated with systemic anticoagulation.
CVO can occur in patients being treated with Coumadin for systemic anticoagulation. Final visual acuity and perfusion status were similar to those in a cohort of patients with CVO who were not treated with Coumadin. Although visual acuity is unaffected, ensuring that the INR for these patients remains in the therapeutic range may be important to help prevent secondary systemic thrombotic and embolic disease.
描述在接受香豆素进行慢性抗凝治疗时发生视网膜中央静脉阻塞(CVO)的患者的临床特征。
在一个回顾性、比较性、非干预性病例系列中,对诊断为CVO且正在接受香豆素作为全身抗凝剂治疗的患者,将其视力和解剖学结果与一组诊断为CVO但未接受任何全身抗凝治疗的患者进行比较。
确定了14例接受香豆素治疗的患者的14只眼。就诊时,国际标准化比值(INR)中位数为2.20(范围1.3 - 5.0)。8例患者(57%)在发生CVO时INR处于治疗范围。他们的视力和灌注状态与INR未达治疗水平的患者相似。在最后一次随访时(中位数为16个月),14只眼组的视力和灌注状态与基线检查结果相似(P = 0.62)。临床特征和结果与一组未接受全身抗凝治疗的CVO患者相似。
接受香豆素进行全身抗凝治疗的患者可能发生CVO。最终视力和灌注状态与未接受香豆素治疗的CVO患者队列相似。尽管视力未受影响,但确保这些患者的INR保持在治疗范围内对于预防继发性全身血栓形成和栓塞性疾病可能很重要。